In a few days time, the 11th edition of the European Breast Cancer Conference (EBCC-11) will begin in Barcelona (21-23 March 2018).
This conference will provide a unique multidisciplinary setting for health care professionals with a common interest in breast cancer to discuss, debate, inform and educate themselves about this evolving disease landscape.
The aim of EBCC is to provide a European multidisciplinary platform for scientific exchanges on all aspects of breast cancer, from bench to bedside.
EORTC will welcome you on booth B2. We will be presenting results from two EORTC studies in the main plenary sessions:
- Trasutuzumab versus observation for high-risk, non-metastatic, HER2 non-amplified breast cancer with Circulating Tumor Cells (EORTC 90091-10093 Treat CTC): A European, multicenter, randomized phase 2 trial
Plenary Session: “Keynote Lecture, Best and Late Breaking Abstract Presentations”
Time: 21 March 2018 at 15:15
Authors: M. Ignatiadis, S. Litiere, F. Rothe, S. Riethdorf, C. Proudhon, T. Fehm, K. Aalders, H. Forstbauer, P. Fasching, E. Brain, P. Vuylsteke, E. Guardiola, R. Lorenz, K. Pantel, K. Tryfonidis, W. Janni, M. Piccart, C. Sotiriou, B. Rack, J.Y. Pierga
- Very low risk of locoregional breast cancer recurrence in the EORTC 10041/BIG 03-04 MINDACT trial: analysis of risk factors including the 70-gene signature.
Closing Plenary Session : “Keynote Lecture, Best and Late Breaking Abstract Presentations”
Time: 23 March 2018 at 15:05
Authors: E. Rutgers, K. Aalders, C. Poncet, F. Cardoso, J. Bogaerts, S. Delaloge, A. Thompson, K. Tryfonidis, L.J. van’t Veer, M. Piccart, I.T. Rubio for the MINDACT Investigators